SCHEMBL721439

SCHEMBL721439

Cc1c(C(Nc2ccc(C(=O)O)cc2)C2CCCCC2)oc2ccc(F)cc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
RCE1 Q9Y256 1/20 0.41
ALDH1A1 P00352 2/20 0.40
TEAD4 Q15561 1/20 0.39
HCRTR1 O43613 1/20 0.39
PPARG P37231 1/20 0.39
NCOR2 Q9Y618 1/20 0.39
MAPT P10636 3/20 0.38
ATM Q13315 1/20 0.37
KDM4E B2RXH2 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HSD17B10 Q99714 1/20 0.36
PDE7A Q13946 1/20 0.36
LTA4H P09960 1/20 0.36
OPRK1 P41145 1/20 0.35
MITF O75030 1/20 0.35
HTR2B P41595 1/20 0.35
CA12 O43570 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14905653 0.99 NPC1 (0.49) NPC1RAB9ARCE1ALDH1A1TEAD4
SCHEMBL719110 0.92 NPC1 (0.41) NPC1RAB9ARCE1ALDH1A1TEAD4
SCHEMBL14905708 0.89 NPC1 (0.48) NPC1RAB9AALDH1A1HCRTR1PPARG
SCHEMBL718462 0.88 NPC1 (0.48) NPC1RAB9AALDH1A1TEAD4HCRTR1
SCHEMBL721199 0.87 NPC1 (0.48) NPC1RAB9A
SCHEMBL720543 0.87 NPC1 (0.52) NPC1RAB9ARCE1ALDH1A1MAPT
SCHEMBL719816 0.86 NPC1 (0.41) NPC1RAB9ARCE1ALDH1A1TEAD4
SCHEMBL720080 0.86 NPC1 (0.47) NPC1RAB9AALDH1A1ATM
SCHEMBL719224 0.86 NPC1 (0.44) NPC1RAB9ATEAD4MAPTOPRK1
SCHEMBL718372 0.86 RCE1 (0.39) NPC1RAB9ARCE1ALDH1A1TEAD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885RCE1 2661/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP NPC1 902/4885RAB9A 2454/4885RCE1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.